A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors

Table 1 Dose-escalation cohorts and DLTs

Dosing cohort	Troriluzole, continuous oral dosing	Nivolumab q 2 weeks	Patients treated (n)	DLTs (n)
Cohort 1	140 mg PO QHS	240 mg	3	0
Cohort 2	140 mg PO QAM 140 mg PO QHS	240 mg	6	1 (anorexia)
Cohort 3	140 mg PO QAM 280 mg PO QHS	240 mg	3	0
Cohort 4	280 mg PO QAM 280 mg PO QHS	240 mg	2	2 (fatigue and atrial fibrillation)

ISSN: 2047-783X